2JQ Stock Overview A clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Gritstone bio, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Gritstone bio Historical stock prices Current Share Price US$0.042 52 Week High US$2.73 52 Week Low US$0.04 Beta 0.76 1 Month Change 0% 3 Month Change -76.34% 1 Year Change -97.70% 3 Year Change -99.31% 5 Year Change -99.52% Change since IPO -99.69%
Recent News & Updates
Gritstone Bio, Inc. Announces CEO Changes Jan 05 Gritstone Bio, Inc. Announces Resignation of Executives
Gritstone bio, Inc. Announces Encouraging Updated Interim Phase 2 Data from Ongoing Phase 2 Study Evaluating GRANITE Nov 12 Motion for Asset Sale Filed by Gritstone bio, Inc. Oct 24
Gritstone bio, Inc.(OTCPK:GRTS.Q) dropped from NASDAQ Composite Index Oct 22
Gritstone bio Receives Delisting Notice from Nasdaq Due to Chapter 11 Case and it Does Not Intend to Appeal the Determination Oct 17 See more updates
Gritstone Bio, Inc. Announces CEO Changes Jan 05 Gritstone Bio, Inc. Announces Resignation of Executives
Gritstone bio, Inc. Announces Encouraging Updated Interim Phase 2 Data from Ongoing Phase 2 Study Evaluating GRANITE Nov 12 Motion for Asset Sale Filed by Gritstone bio, Inc. Oct 24
Gritstone bio, Inc.(OTCPK:GRTS.Q) dropped from NASDAQ Composite Index Oct 22
Gritstone bio Receives Delisting Notice from Nasdaq Due to Chapter 11 Case and it Does Not Intend to Appeal the Determination Oct 17
New major risk - Market cap size Oct 11
Gritstone Bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer Oct 01
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.31 loss in 2Q 2023) Aug 15
Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement Jun 27
Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement Jun 26
New major risk - Revenue and earnings growth May 14
First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.30 loss in 1Q 2023) May 11 Gritstone bio, Inc. to Report Q1, 2024 Results on May 09, 2024
Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024 May 01
Gritstone Bio, Inc. Announces Board Changes Apr 30
Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform (SLATE) Apr 15
New minor risk - Market cap size Apr 12 Gritstone bio, Inc. has completed a Follow-on Equity Offering in the amount of $32.5 million. Apr 03
Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite
Full year 2023 earnings released: US$1.20 loss per share (vs US$1.32 loss in FY 2022) Mar 06
Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial Feb 12
Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna (Samrna) Vaccine Candidates Against Covid-19 (Part of the Company’s Coral Program) at IDWeek 2023 Oct 12
Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.34 loss in 2Q 2022) Aug 10
New major risk - Financial position Jul 02
Gritstone bio, Inc. to Report Q1, 2023 Results on May 11, 2023 May 04
Full year 2022 earnings released: US$1.32 loss per share (vs US$0.95 loss in FY 2021) Mar 11
Gritstone bio, Inc. Announces Updated Overall Survival Results from Granite Phase 1/2 Study and Poster At Sitc 2022 Nov 11
Third quarter 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in 3Q 2021) Nov 05 Gritstone bio, Inc. announced that it expects to receive $44.999991 million in funding from Redmile Group, LLC, Gilead Sciences, Inc., The Invus Group, LLC, Hercules Capital, Inc. and other investors
Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022 Sep 13
Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors Aug 16
Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022 Aug 11
Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.33 loss in 2Q 2021) Aug 05
Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Index Jun 26
Gritstone Announces Results from Preclinical Study of Its Self-Amplifying Mrna (Samrna) Vaccine Against Sars-Cov-2 Published in Nature Communications Jun 11
Gritstone Bio, Inc. Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of Granite and Trial in Progress Poster At Asco Jun 01
First quarter 2022 earnings released: US$0.33 loss per share (vs US$0.16 profit in 1Q 2021) May 06
Gritstone bio, Inc. to Report Q1, 2022 Results on May 05, 2022 May 03
Less than half of directors are independent Apr 27
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 16
Less than half of directors are independent Mar 16
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC) Jan 14
Less than half of directors are independent Jan 06
Gritstone Bio, Inc. Announces Positive Clinical Results from First Cohort of A Phase 1 Study (CORAL-BOOST) Evaluating A T Cell-Enhanced Self-Amplifying mRNA (SamRNA) Vaccine Against COVID-19 Jan 05
Gritstone bio, Inc Announces Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines Dec 01
Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer Sep 21 Gritstone Bio, Inc. Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial
Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021 Sep 11
Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.69 loss in 2Q 2020) Aug 08
High number of new directors Jul 29 Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Growth Index
First quarter 2021 earnings released: EPS US$0.10 (vs US$0.71 loss in 1Q 2020) May 06
Full year 2020 earnings released: US$2.79 loss per share (vs US$2.81 loss in FY 2019) Mar 13
Revenue beats expectations Mar 13
Gritstone Oncology, Inc. Announces Promotions Within its Leadership Team Mar 10 Gritstone Oncology, Inc Announces Board Appointments
Executive VP & CTO recently sold €182k worth of stock Jan 23
Gritstone Oncology, Inc. and Genevant Sciences Announce License Agreement for COVID-19 Vaccine Jan 22
Gritstone Oncology, Inc. Advances Development of Second Generation Vaccine Against SARS-CoV-2 Jan 20
New 90-day high: €4.70 Jan 13 Gritstone Oncology, Inc. announced that it expects to receive $15.000001 million in funding
New 90-day high: €3.34 Dec 24
Gritstone Oncology, Inc. announced that it expects to receive $110 million in funding from Avidity Partners Management LP, EcoR1 Capital, LLC, Redmile Group, LLC, and other investors Dec 24
Gritstone Oncology, Inc Announces Resignation of Jean-Marc Bellemin as Chief Financial Officer Dec 06
New 90-day low: €2.16 Nov 07
Third quarter 2020 earnings released: US$0.69 loss per share Nov 07
Revenue misses expectations Nov 07
Gritstone Oncology, Inc. Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE Nov 03
New 90-day low: €2.32 Sep 25
Gritstone Oncology, Inc.(NasdaqGS:GRTS) dropped from S&P Global BMI Index Sep 21
New 90-day low - €2.72 Aug 25 Shareholder Returns 2JQ DE Biotechs DE Market 7D 0% 5.8% 2.0% 1Y -97.7% -6.1% 9.6%
See full shareholder returns
Return vs Market: 2JQ underperformed the German Market which returned 9.1% over the past year.
Price Volatility Is 2JQ's price volatile compared to industry and market? 2JQ volatility 2JQ Average Weekly Movement n/a Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2JQ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 2JQ's volatility change over the past year.
About the Company Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.
Show more Gritstone bio, Inc. Fundamentals Summary How do Gritstone bio's earnings and revenue compare to its market cap? 2JQ fundamental statistics Market cap €1.07m Earnings (TTM ) -€128.34m Revenue (TTM ) €14.09m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2JQ income statement (TTM ) Revenue US$14.61m Cost of Revenue US$119.55m Gross Profit -US$104.94m Other Expenses US$28.09m Earnings -US$133.03m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.90 Gross Margin -718.30% Net Profit Margin -910.56% Debt/Equity Ratio 182.5%
How did 2JQ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/07 05:55 End of Day Share Price 2024/10/14 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Gritstone bio, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Madhu Kumar Baird Corinne Johnson Goldman Sachs Douglas Buchanan JMP Securities
Show 1 more analysts 
